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ABSTRACT
The antiviral response to influenza virus is complex and multifaceted, involving many immune cell subsets. There is an urgent need to
understand the role of CD4+ T cells, which orchestrate an effective antiviral response, to improve vaccine design strategies. In this
study, we analyzed PBMCs from human participants immunized with influenza vaccine, using high-dimensional single-cell proteomic
immune profiling by mass cytometry. Data were analyzed using a novel clustering algorithm, denoised ragged pruning, to define
possible influenza virus–specific clusters of CD4+ T cells. Denoised ragged pruning identified six clusters of cells. Among these, one
cluster (Cluster 3) was found to increase in abundance following stimulation with influenza virus peptide ex vivo. A separate cluster
(Cluster 4) was found to expand in abundance between days 0 and 7 postvaccination, indicating that it is vaccine responsive. We
examined the expression profiles of all six clusters to characterize their lineage, functionality, and possible role in the response to
influenza vaccine. Clusters 3 and 4 consisted of effector memory cells, with high CD154 expression. Cluster 3 expressed cytokines
like IL-2, IFN-g, and TNF-a, whereas Cluster 4 expressed IL-17. Interestingly, some participants had low abundance of Clusters 3 and
4, whereas others had higher abundance of one of these clusters compared with the other. Taken together, we present an approach
for identifying novel influenza virus–reactive CD4+ T cell subsets, a method that could help advance understanding of the immune
response to influenza, predict responsiveness to vaccines, and aid in better vaccine design. ImmunoHorizons, 2020, 4: 774–788.
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Influenza virus infection is a serious health concern, especially in
children, elderly patients, and those with respiratory disorders
or other chronic medical conditions. The influenza vaccine is
important to protect the general population from contracting the
disease and is especially critical for high-risk groupswhowill need
more frequent hospitalizations and suffer complications from
infection and even mortality. Unfortunately, the current influenza
vaccine must be developed, produced, and administered every
year, based on the predicted reassortment of viral strains for that
specific year. The effectiveness of the vaccine can vary drastically
by viral strain from season to season and among different age and
risk groups (1–3).
Conventionally, the immune response to influenza virus has
been characterized by the B cell–mediated production of virus-
specific neutralizing or agglutinating IgG Abs. Hence, the
hemagglutination inhibition (HAI) assay iswidely used tomeasure
protective immunity to influenza virus. Most vaccine develop-
ment and evaluation has thus focused on this arm of the
immune system. However, in light of the limited effectiveness
of the current influenza vaccine, there is a need to diversify
vaccine design approaches, possibly by including strategies for
T cell activation (4–7). To this end, there is great interest in
studying the role of T cells, especially CD4+ T cells, in the
generation and shaping of the immune response to influenza
virus (8–12). CD4+ T cells play a multifaceted role in the
antiviral response to influenza viruses, including the important
aspect of B cell help provided by T follicular helper (Tfh) cells
(13, 14). First, CD4+ T cells provide B cell help for the initiation
of germinal centers and the generation of high-affinity Abs (15).
Furthermore, they are also important in the generation and
expansion of CD8+ memory T cell subsets, which can mount
effective cytotoxic responses to virally infected cells (16, 17).
Finally, a subset of cytolytic CD4+ T cells have been shown to be
protective in influenza and could serve as an additional avenue to
boost the immune response (6, 18). Because CD4+ T cells are a
vastly heterogeneous population, it is imperative to identify
specific subsets that are key players in immunity to influenza
virus. The frequency of T cells specific for influenza virus Ags in
blood is low, making it important to determine that the cells being
studied are actually vaccine responsive, including those that arise
from naive T cells, as well as pre-existing memory T cells
generated during previous vaccination and/or exposure to in-
fluenza viruses (19). Such efforts can eventually guide vaccine
design to create the next generation of more effective and broadly
reactive influenza vaccines.
In this study,we performed a detailed phenotypic and functional
characterization of PBMCs from donors before vaccination (day 0)
and after vaccination (day 7) with trivalent inactivated influenza
vaccine (TIV). Using mass cytometry by time of flight (CyTOF), we
were able toperformhigh-dimensional single-cell immuneprofiling,
with the goal of identifying influenza virus–specific immune cell
subsets. In this study,weusedanovelmethodcalleddenoised ragged
pruning (DRP, Fig. 1) for the specific purpose of determining
influenza virus–specific CD4+ T cell phenotypes.
Several algorithms are in use for clustering of data acquired via
mass cytometry [Table II in (20)]. DRP is specially designed to be
applicable in small datasets (i.e., low total cell counts) in two
important respects. First, DRP begins with a denoising step. A
prominent area of active research in CyTOF data analysis is noise
reduction, in which sources of noise are many and diverse (20).
Denoising can be especially useful in small datasets (21). Denoising
removes nonstructural variation in data without “selecting out”
any markers from the analysis. Clustering that includes marker
selection [e.g., as in (22)], although quite useful in general, is not
always applicable in mass cytometry studies because too few
rather than toomanymarkers can be acquired, although in theory,
“high levels ofmultiplexing (.40proteins inparallel) arepossible”
(23). For example, ideally, thepanel ofmarkers in the current study
might have included more markers than just ICOS for definitively
identifying circulating Tfh cells. However, even a large CyTOF
staining panel cannot accommodate all phenotyping and func-
tional markers needed for dissecting the broad immune
response reflected in peripheral blood. Second, as we demon-
strate below, the DRP pruning algorithm permits isolation of
rare phenotypes. This propertymight distinguishDRP from the
related method of Citrus (24) because DRP includes an initial
denoising step, a different method for ragged pruning (Fig. 1D),
and optimal pruning. Differential analysis of cydar is an
interesting alternative approach that may outperform Citrus
for detecting phenotypes (25), deterministic spanning-tree
progression analysis of density-normalized events (SPADE)
employs outlier removal and systematic downweighting to
facilitate detection of rare phenotypes (26), and X-shift’s
weighted k-nearest-neighbor density estimation algorithm has
been demonstrated to recover additional phenotypes not
identified via manual gating as well as transitional phenotypes
(27); however, neither cydar, SPADE, nor X-shift includes an
initial denoising step to facilitate resolution of phenotypic
structure, a step that may be crucial in the analysis of data
consisting of low total cell counts. Indeed, DRP is designed for
datasets containing (10,000 total cells.
The “denoised” component of the DRP algorithm (Fig. 1B)
isolates and removes noise from the signal intensity dataset prior
to clustering. Additionally, cell subsets of interest can vary
considerably in relative abundances (e.g., Fig. 2, vertical axis).
DRP’s “ragged-pruning” component (Fig. 1, Step D) permits
estimation of all distinct cell phenotypes, whether represented by
small or very large quantities of individual cells in the dataset.
Taken together, these two targeted properties make DRP
invaluable in the study of cell subsets that may be rare and of
subtle but distinct variations. Using DRP, we were able to
identify two relevant CD4+ T cell clusters from the CyTOF data,
one of which appears to be a pre-existing influenza virus–
specific cluster, and the other was an influenza vaccine–
responsive cluster.We further characterized expression profiles
of these clusters to understand their possible functional role in
the immune response to influenza virus.
https://doi.org/10.4049/immunohorizons.1900097
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Blood sampleswere collected from46healthy donors prior to (day
0) and7d after (day 7) influenzavaccination. All study participants
were healthy donors, with samples collected under Institutional
Review Board–approved influenza vaccine studies at Stanford
University (SU; two separate studies) and Baylor Institute for
Immunology Research (BIIR; one study). Age range was 12–80 y
(median=42y); detailedage/gender information is shown inTable
I. All participants received the seasonal TIV during the period of
2009–2012.
PBMC collection and storage
Heparinized blood was subjected to Ficoll-Hypaque gradient
separation, and PBMC were cryopreserved using standard
protocols. Samples collected at BIIR were shipped to SU on dry
ice, but all samples were otherwise stored in liquid nitrogen until
thawing for CyTOF analysis, as described below.
CyTOF intracellular cytokine staining assay
Cells were stained and prepared for CyTOF analysis as previously
described (28). Briefly, frozen PBMC samples from participants
were thawed and resuspended in complete medium (RPMI
1640 supplemented with 10% FBS, penicillin, streptomycin, and
L-glutamine)with benzonase. Afterwashing, cellswere counted,
and 23 106 cells (or maximum available) were placed in a 96-well
U-bottom plate in complete medium (benzonase-free). Cells were
rested overnight at 37°C and 5% CO2. Cells were then stimulated
for 8hwith 1mg/ml eachof hemagglutinin (HA)PepMix Influenza
A California H1N1 (139 peptides) and NP PepMix Influenza A
H3N2 (122 peptides), both fromJPTPeptideTechnologies (Berlin,
Germany). We chose this HA+NP peptide mix because although
current inactivated influenza virus vaccines are partly purified and
standardized for their HA content, there are some levels of NP
present in them. The secretion inhibitormonensin fromBiolegend
(San Diego, CA), 2 mg/ml anti-CD40 from Miltenyi Biotec
(Bergisch Gladbach, Germany), and 1 mg/ml anti-CD28/CD49d
FIGURE 1. Schematic representation of DRP algorithm.
(A) The original data matrix has individual cells as rows and cell surface
markers as columns. (B) A principal components analysis is performed
on this original data matrix, and the data matrix is denoised by hard
eigenvalue thresholding (red line). (C) An initial tree is created based on
an agglomerative hierarchical clustering of the denoised data. (D) This
tree is then pruned back to create a set of clusters (circles of different
colors) that equal or exceed the first minimum cell count (e.g., illus-
trated in this study with minimum of four). (E) This pruning process is
repeated for each successively larger minimum cell count. (F) The
optimal cluster solution is from that minimum cell count of greatest
improvement in cluster quality relative to next smallest minimum cell
count. Together, (D) and (F) illustrate the formation of nested clusters
(see Materials and Methods). Actual trees will be many times larger than
depicted in this study because total cell counts will equal or exceed O
[103]. For this reason, DRP is computer-memory demanding. The figure
was generated using R package dendextend (64), R package MASS (65),
base R (43), and Microsoft PowerPoint and Word and Windows Paint
(Microsoft Corporation, Redmond, WA). See Statistical Methods and
also see Section S1.2.2 in Bruggner et al. (24).
https://doi.org/10.4049/immunohorizons.1900097
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FIGURE 2. Estimated proportions of all six clusters identified by DRP.
The estimated proportions of each cluster identified by DRP at day 0 and day 7 are represented graphically. Left panels show the influenza
peptide–stimulated condition, and right panels show the unstimulated condition. Each line represents a single study participant. *p , 0.05. Black
star symbols are estimated mean proportions for that cluster, stimulation condition, and day with the numeric values reported to four to five decimal
places. The estimates of mean proportions differ from Table III because they are without correction for regression covariates. The figure was
prepared in SAS ODS Graphics (SAS Institute).
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fromBDBiosciences (San Jose, CA)were also added (the latter for
costimulation, the former to prevent CD40L downmodulation).
Anti-CD107a labeled with 154Sm (conjugated in-house) was also
added during stimulation to allow labeling of transiently expressed
CD107a. After 4 h, 5 mg/ml brefeldin A from Sigma-Aldrich (St.
Louis, MO) was added, and the plate was incubated for another
4 h at 37°C. Surfacemarkers were stained using amixture of metal
ion-conjugatedAbsdiluted inCyFACSbuffer (metal-freePBS from
RocklandImmunochemicals [Pottstown,PA]with0.1%BSA,2mM
EDTA, and 0.05% sodium azide) (Table II). Preconjugated Abs
from Fluidigm (South San Francisco, CA), as well as in-house
conjugated Abs, were included in the panel (Table II). 115In
Maleimide-DOTA fromMacrocyclics (Plano, TX) was used for
LIVE/DEAD staining as per the supplier’s recommendations.
Cells were fixed in 2% paraformaldehyde diluted in metal-free
PBS from Rockland Immunochemicals and permeabilized
using permeabilization buffer from eBioscience (Thermo
Fisher Scientific, Waltham, MA). These fixed and permeabi-
lized cells were stained using an intracellular Ab mixture
diluted in permeabilization buffer (Table II). Finally, cells were
stained with 191Ir and 193Ir DNA intercalator from Fluidigm, as
per the manufacturer’s directions. Samples were washed twice
in CyFACS and 3 times in Milli-Q water before running. EQ
Four Element Calibration beads from Fluidigm were added to
the sample as directed. Datawere acquired on aCyTOFVersion
1 instrument from Fluidigm.
CyTOF data analysis
Raw data were obtained from CyTOF as .fcs files. Using the
calibration beads, these data were normalized for instrument
performance using the Nolan Lab MATLAB-based normalizer,
which is freely available on Github (https://github.com/nolanlab/
bead-normalization). Thereafter, the normalized .fcs files were
loaded into FlowJo (Version 9.9.4) from Tree Star (Ashland, OR).
Sequential gating of CyTOF data was performed as described
previously (28). Briefly, gating on events positive for both DNA
markers 191Ir and 193Ir (DNA1 and DNA2) was used to identify
intact cells. DNA marker along with event length were used to
gate intact singlets. We then used 115InMaleimide-DOTA (a dead
cell stain) to gate on live intact singlets. Based on CD14 and CD33
expression, these live intact singlets were further gated into
lymphocytes (CD142CD332) andmonocytes (CD14+CD33+). CD3
expression on lymphocytes was used to identify CD3+ T cells.
T cells were then gated as CD4+ andCD8+ (28). TheCD4+ T cell
population from each sample was further analyzed for the
expression of five cytokines: IFN-g, IL-2, IL-17, TNF-a, and
MIP1b (Supplemental Fig. 1). Boolean logicwas used to identify
cells that express any one or more of these five cytokines.
Expression data on all panelmarkers on each of these cytokine+
cells were exported and tabulated for further statistical
analysis as described below. Statistical analyses on these gated
cytokine+ CD4+ T cells were limited to 32 markers relevant to
T cells. The B cell marker CD19 and monocyte markers CD14
and CD33 were used for basic lineage gating but excluded from
further statistical analysis. Also, two poor-performingmarkers,
IL-10 and FOXP3, were excluded prior to the initiation of these
statistical analyses. The T cell–relevant markers used for
analysis were as follows: CXCR3, CCR6, CD57, CD69, CD4,
CD8, CD3, MIP1b, CD85j, CD45RA, CD38, TNF-a, Granzyme,
CD107a, GMCSF, CD154, IL-2, IFN-g, HLA-DR, Ki67, ICOS,
IL-17, CD127, CD27, CCR7, PD1, CXCR5, IL-21, Perforin, CD16,
CD56, and CD25.
Statistical methods
Cluster analysis. Separately for each of the 32 markers, raw
intensity data y were transformed as x = Arsinh[y5] and then
centered and scaled as t = (x 2 x)/s for sample mean x and
corresponding sample SD s. Altogether, these transformedmarker
data formed data matrix T (one column per marker, and one row
for each cell) for analysis (Fig. 1A). This data matrixTwas used to
estimate cell clusters via the application of our newly developed
DRP clustering algorithm. DRP consists of five basic steps as
follows. 1)Denoising (Fig. 1B)wasperformed to separate structural
components (e.g., biological structure) from noise components
(e.g., technical error) (21). Structure was defined as the principal
components of data matrix T with eigenvalues exceeding the
90th percentile of the null eigenvalue distribution (29). (Each
eigenvalue is the sample variance of its corresponding principal
component (30). Large eigenvalues indicate the presence of
structure in data. Null eigenvalues are small and arise from
structureless noise.) 2) Agglomerative hierarchical clustering (31),
a form of cluster analysis, was performed on the principal
components of large eigenvalues (i.e., structural principal compo-
nents) of data matrix T (Fig. 1C). 3) The resultant hierarchical
clustering tree was “pruned” back in possibly ragged fashion (Fig.
1D). A tree is a graph (32) that, in this study, displays hierarchical
relationships among clusters of cells. The “branch tips” of the tree
are individual cells. Moving from the branch tips to the “trunk,”
clusters of cells are sequentially merged into larger and larger
clusters of more cells, ending at the trunk of the tree, in which all
cellshavemerged into a single cluster. Pruning thebranches of this
tree creates pruned branch tips that, together, represent a set of
(merged) clusters, with each cell occurring in one cluster only. 4)
Pruning was repeated many times, each time with a progressively
larger criterion for minimum quantity of cells per “pruned
branched tip” (Fig. 1E). Minimum quantity of cells was varied
from 10 cells to ;20% of input sample size in increments of 50
cells. A set of cells are assigned to a cluster when they first form a
branch with a quantity of cells equaling or exceeding the
minimum. For example, suppose the minimum size is four, and
two cells branch from an existing cluster of four cells. Those two
cells are assigned to their owncluster (e.g., two blue clusters in Fig.
1F) because 2 +4.4.This facilitates discovery of rare phenotypes.
5) The final step identified that pruning yielded a cluster solution
of the highest increase in average cluster quality (33) with an
increase in that minimum quantity of cells (Fig. 1E). Optimal
cluster solution is illustrated in a heat map of mean Arsinh-
transformed expression by marker and cluster and in penalized
supervised star plots of Arsinh-transformed expression for all
markers together (34).
https://doi.org/10.4049/immunohorizons.1900097
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DRP reproducibility and computational speed. DRP’s pruning for
an optimal cluster solution is thorough and thereby computation-
ally intensive. As such, we recommend running DRP on samples
sizes that do not exceed ;10,000 cells. We achieved these cell
counts through stratified random downsampling. Stratification
was on each combination of study (two at SU and one at BIIR),
batch, participant, visit, and stimulation condition. Stratified
random sampling allowed us to achieve less inequality in cell
counts input to DRP such that all strata would be weighted less
unequally in the cluster solution (Supplemental Fig. 2A).
Specifically, within each stratum, sampling was random without
replacement (35) and with sample size per stratum being the
smaller of 88 cells or a sampling percentage of 90%. This rule
yielded a downsampling percentage of;50% (i.e., approximately
half of all available cells were analyzed via DRP) per run of DRP.
The DRP algorithm was run on three separate stratified random
50% downsamplings to examine the reproducibility of results
across different random downsamples. This resulted in three
separate DRP cluster solutions (Supplemental Fig. 2B). In
Supplemental Fig. 2B, for heat map labels at right, the first
two digits are percentage of downsampling, third digit is
downsampling identification number (1–3), and last digit(s)
is(are) DRP cluster identification number within that down-
sampling (1, 2, 3, ...). Quantities of DRP clusters varied among
downsamplings, the highest at 18 clusters for the third down-
sampling. In dendrogram at left (Supplemental Fig. 2B), longer
horizontal line segments indicate greater separation in marker
expression among clusters at that level in the dendrogram.
Vertical yellow line was approximately placed where this
separation is greatest, and this line cuts the dendrogram in seven
places, yielding sixmajorcombinedclusters. Seventh rare isolated
cluster marked by an “X” was excluded from further analyses
(Supplemental Fig. 2B). Clusters are termed “combined” because
of combining across closely related clusters from different
downsamplings and combining closely related clusters within
the same downsampling, with all combining accomplished by
cutting the dendrogram at the vertical yellow line. Note that a
given cell may occur in more than one downsampling and that
admits the possibility that cells may occur in more than one of
these sixmajor combined clusters.With all three downsamplings
combined and the one cluster marked with an X removed, the
dataset contained 15,015 cells with 3,828 cells (;25%) appearing in more than one of the combined clusters because of the three
randomdownsamplings.Wedroppedanycells that occurredwith
equal frequency inmore than one cluster. For example, suppose a
cell was randomly selected in two downsamplings but assigned to
twodifferentmajor combined clusters; that cellwasdropped.The
same rule applied to a cell assigned to three different major
combined clusters. Together, these accounted for ;10% of the
15,015 cells. Any cell that only occurred in one major combined
cluster (11,187 cells,;75%)was retained. Any cell that occurred in
onemajor combined cluster twice andadifferentmajor combined
cluster once was retained for analysis (2279 cells, ;15%) and
assigned to that major combined cluster where it occurred twice
(majority vote). For each cell removed (numerator),we decreased
the total CD4 count (denominator) by one.
TABLE I. Age and gender distribution of participants in study
Male Female Total
Age (y)
,30 8 7 15
30–39 3 3 6
40–49 3 9 12
50–59 4 7 11
60–69 0 1 1
.70 0 1 1
Total 18 28 46
% of total 39.13% 60.87% 100.00%
Median age of the cohort was 42 y.
TABLE II. CyTOF intracellular cytokine staining panel
Specificity Metal Tag Source









































Nonprotein subjects are shown in italics. 115In-Maleimide-DOTA, a live-dead
stain, and 191Ir and 193Ir (DNA intercalators) are used to detect live intact singlets.
The calibration beads allow us to normalize data for instrument performance.
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Comparing cluster proportions. From the estimated optimal
cluster solution (Fig. 1F), numerators and denominators of cell
counts were tabulated. Numerator n was the cell count for each
combination of study, batch, participant, visit, stimulation condi-
tion, and cluster and zero for any such combination without cells.
Denominator d was the gated total CD4+ T cell count. These
yielded an estimated cluster proportion per combination of study,
batch, participant, visit, and stimulation condition of r = n/d. For
each cluster, sample sizes (of participants) were 48, 48, 47, and 47
for day 0 unstimulated, day 0 stimulated, day 7 unstimulated, and
day 7 stimulated, so two data values were missing. A regression
model was fit separately for each cluster. Observed proportion r
was regressed on visit, stimulation condition, the interaction of
visit andstimulation condition, study (to account foranyotherwise
unmeasured differences in the three sampled populations),
elapsed days from start of study for batch (batch day), and the
interaction of study and batch day. The interaction of visit and
condition allowed differences in cluster proportions between
conditions to vary with visit and the converse. The interaction of
study and batch day allowed any trends in proportions over time
across batches to vary among studies. Outcome r was modeled as
a binomial proportion; however, unlike a standard binomial
distribution in which the denominator is constant, the denomina-
tor d in this study varies among participants and stimulation
conditions within participants. For this reason, we employed
fractional logistic regression with a robust estimator of the
variance (36, 37) and random coefficients (i.e., mixed-effects
model) for participants. These random coefficients are additional
predictor variables that account for participant-specific variation
in mean r not explained by visit, stimulation condition, the
interaction of visit and stimulation condition, study, batch day, and
the interaction of study and batch day. From the fit of the
regression model, the average participant’s difference in means of
proportions r between 1) stimulation conditions within each visit
and 2) visits within each stimulation conditionwere estimated. All
p values were adjusted for multiple comparisons (38) across all
comparisons (i.e., visit comparisons combined with stimulation
comparisons for all clusters).
Cluster proportions association with clinical outcome. Separately
for each strain,HAI titer at day 28was regressed on the stimulated
proportion of each cluster r at day 0 (baseline), study, and baseline
HAI titer. Baseline HAI titer was employed as a covariate rather
than formulating the outcome as fold change (day 28 divided by
baseline) to improve statistical power (39). Because a titer of h
indicates that true titer falls somewhere in the half-closed interval
[h, 2h), analysis employed regression methods for interval-
censored outcome data (40, 41). In a separate, secondary analysis,
for each strain,HAI titer at day 28was regressed on the stimulated
proportion of each cluster r at day 7, study, and baseline HAI titer.
Missing CyTOF and HAI data were multiply imputed using fully
conditional specification with predictive mean matching (42).
Fifty complete datasets were generated 1) with missing values for
HAI titer imputed using predictors ofHAI strain, study, day 0, and












1 0 Stim 0.005287 0.000854 0.003834995 0.007285690
1 0 Unstim 0.004563 0.000921 0.003053719 0.006812640
1 7 Stim 0.005154 0.000842 0.003723868 0.007128893
1 7 Unstim 0.004473 0.000900 0.002998645 0.006668867
2 0 Stim 0.000204 0.000090 0.000084928 0.000489135
2 0 Unstim 0.000148 0.000065 0.000061416 0.000355026
2 7 Stim 0.000199 0.000084 0.000085881 0.000460072
2 7 Unstim 0.000152 0.000068 0.000062763 0.000368067
3 0 Stim 0.003910 0.001195 0.002128751 0.007171356
3 0 Unstim 0.001666 0.000547 0.000867630 0.003197555
3 7 Stim 0.003798 0.001178 0.002049616 0.007026867
3 7 Unstim 0.001645 0.000550 0.000846333 0.003194069
4 0 Stim 0.000253 0.000065 0.000151905 0.000422264
4 0 Unstim 0.000442 0.000131 0.000245043 0.000798285
4 7 Stim 0.000292 0.000069 0.000181568 0.000468155
4 7 Unstim 0.000439 0.000125 0.000249725 0.000772443
5 0 Stim 0.000029 0.000023 0.000006284 0.000137423
5 0 Unstim 0.000018 0.000015 0.000003307 0.000093301
5 7 Stim 0.000029 0.000022 0.000006295 0.000130341
5 7 Unstim 0.000017 0.000014 0.000003317 0.000087339
6 0 Stim 0.000099 0.000046 0.000039411 0.000248397
6 0 Unstim 0.000085 0.000045 0.000029555 0.000243408
6 7 Stim 0.000093 0.000042 0.000037480 0.000228578
6 7 Unstim 0.000075 0.000037 0.000028068 0.000201457
Estimated mean proportions of total CD4+ T cells (and their SEs and 95% confidence intervals) by cluster, days elapsed following vaccination (day 0 or day 7), and
stimulation condition. Estimates were obtained from fit of regression model (see Statistical Methods); in contrast to Fig. 2, estimates have been adjusted for covariates.
Stim, stimulated with HA1NP peptide mix; Unstim, unstimulated.
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day 7 proportions for all six clusters and 2) withmissing values for
day7proportionsof all sixclusters imputedusingpredictorsofHAI
strain, study, day 0 and day 28HAI titers, and day 0 proportions for
all six clusters.
Software. Statistical analyses were performed in SAS (SAS Institute,
Cary, NC), base R (43), and R packages cwhmisc (44), Weight-
edCluster (45), heatmap3 (46), matrixcalc (47), plotrix (48), JPEN
(49), sampling (50), VCA (51), rospca (52), and tsne (53). Additional
software for generating graphics is listed in the figure legends.
RESULTS
Weusedmass cytometry (CyTOF) to examine the phenotypic and
functional markers of influenza virus–specific T cells prior to and
1wkafter vaccinationwith seasonalTIV(Tables I, II). PBMCwere
unstimulated or stimulated with HA+NP overlapping peptides
prior to the CyTOF assay. CyTOF data were manually gated to
obtain cytokine+ (IFN-g, IL-2, IL-17, TNF-a, or MIP1b) CD4+
Tcells (Supplemental Fig. 1). CyTOFpanelmarker expressiondata
for eachof these cellswere exported, andDRPwasused to identify
influenza virus–specific CD4+ T cell clusters (Fig. 1).
Influenza virus–specific CD4+ T cell clusters identified
by DRP
Using the novel statistical method of DRP, we obtained an
optimized cluster solution for the cytokine+CD4+T cells. A total of
six clusters were identified by this method (Fig. 2). A tabulated list
of estimated proportions of all six clusters at all time points and
stimulation conditions is shown in Table III. Table III clearly
quantifies the extreme rarity of these phenotypes (e.g., stimulation
at 7 dpostvaccinationgenerates approximately two cells ofCluster
2 per 10,000 CD4+ T cells). At each time point, we compared the
abundance of each cluster in influenza virus peptide–stimulated
samples to their unstimulated counterparts. Cluster 3 was
significantly higher in influenza peptide–stimulated versus–
unstimulated conditions (Table IV), suggesting that it is an
influenza virus–specific cluster. Cluster 3 was significantly
higher in the stimulated condition at both day 0 and day 7; thus,
it appears to represent a memory T cell response to influenza
viruses (which may or may not have been increased by
vaccination). In contrast, Cluster 4 was significantly higher at
day 7 after vaccination compared with day 0 in the influenza
peptide–stimulated condition (Fig. 2, Table IV). This indicates
that Cluster 4 is a vaccine-induced CD4+ T cell cluster that may
play an important role in the immune response to the virus. All
other clusters (Clusters 1, 2, 5, and 6) did not show significant
differences between stimulated and unstimulated conditions or
between the two time points (Table IV). They thus represented
T cells that were cytokine producing, but not influenza virus
specific, or that were so rare (e.g., Cluster 6) and/or variable
among participants as to not reach statistically significant
increases above their unstimulated background, given the
number of cells sampled. A complete list of all comparisons
across stimulation conditions and time points is shown in
TABLE IV. All comparisons of mean cluster abundance between time points and between stimulation conditions
Cluster Comparison of Proportions Unadjusted p Value FWE Adjusted p Value
1 Day 0 Stim minus Unstim 0.0640 1.0000
1 Day 7 Stim minus Unstim 0.0516 0.9292
1 Stim day 7 minus day 0 0.0047 0.0987
1 Unstim day 7 minus day 0 0.0915 1.0000
2 Day 0 Stim minus Unstim 0.4473 1.0000
2 Day 7 Stim minus Unstim 0.4403 1.0000
2 Stim day 7 minus day 0 0.4842 1.0000
2 Unstim day 7 minus day 0 0.7225 1.0000
3 Day 0 Stim minus Unstim ,0.0001 ,0.0001
3 Day 7 Stim minus Unstim ,0.0001 ,0.0001
3 Stim day 7 minus day 0 0.0306 0.5811
3 Unstim day 7 minus day 0 0.3643 1.0000
4 Day 0 Stim minus Unstim 0.0193 0.3865
4 Day 7 Stim minus Unstim 0.0624 1.0000
4 Stim day 7 minus day 0 0.0009 0.0203
4 Unstim day 7 minus day 0 0.8316 1.0000
5 Day 0 Stim minus Unstim 0.1595 1.0000
5 Day 7 Stim minus Unstim 0.1043 1.0000
5 Stim day 7 minus day 0 0.6446 1.0000
5 Unstim day 7 minus day 0 0.3587 1.0000
6 Day 0 Stim minus Unstim 0.4075 1.0000
6 Day 7 Stim minus Unstim 0.2231 1.0000
6 Stim day 7 minus day 0 0.3127 1.0000
6 Unstim day 7 minus day 0 0.1544 1.0000
For each cluster, comparisons are of mean proportions of total CD4+ T cells between stimulation conditions within each day and, separately, between days within
each stimulation condition. Days are days elapsed since vaccination, and p values are reported without (unadjusted p value) and with (family-wise error adjusted
p value) correction for multiple comparisons. Comparisons were made from fit of regression model (see Statistical Methods).
FWE, family-wise error; Stim, stimulated with HA1NP peptide mix; Unstim, unstimulated.
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FIGURE 3. Star plots of three of the six total clusters identified by DRP.
Star plots of Clusters 3, 4, and 6 show the expression of various markers represented in two-dimensional space. Individual cells from each cluster
are represented on the star plot as colored dots (3, blue; 4, green; and 6, magenta). Arrows indicate the expression of individual markers. Clockwise
from top left shows day 0 unstimulated, day 0 stimulated, day 7 stimulated, and day 7 unstimulated. Star plots were produced through stratified
random downsampling to 82 cells for each combination of cluster, visit, and condition, which allowed equal weighting of all three clusters for both
visits and both conditions. For this reason, these star plots can only be used to assess patterns in expression and not in abundance. Software
packages for producing star plots were base R plus R packages matrixcalc, plotrix, JPEN, sampling, and VCA, as indicated in the Materials and
Methods. Stim day 7 modified from Holmes et al. (34) with permission from Mary Ann Liebert, Inc., New Rochelle, NY. Stim, stimulated with HA1NP
peptide mix; Unstim, unstimulated.
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Table IV. Furthermore, a tabulated list of estimated propor-
tions of all clusters at all time points and stimulation
conditions is shown in Table III. Table III quantifies the
extreme rarity of these phenotypes (e.g., stimulation at
7 d postvaccination generates approximately two cells of
Cluster 2 per 10,000 CD4+ T cells).
Immunophenotypic characterization of influenza
virus–specific Clusters 3 and 4
Our data showed that Cluster 3 appeared to be influenza virus
specific in that it was significantly more abundant with influenza
peptide stimulation versus theunstimulatedconditionat both time
points (Fig. 2, Tables III, IV). In contrast, Cluster 4 was vaccine
induced, as it was significantly higher in the stimulated condition
at day 7 postvaccination compared with day 0. To explore the
phenotypic and functional differences between these clusters, we
created star plots (Fig. 3). These star plots aremainly used to assess
patterns in expression–qualitative differences beyond abundance.
From the star plots, it is apparent that Cluster 3 is very different
from Cluster 4, mainly in its high expression of cytokines like
IFN-g and TNF-a with CD154 and CD127. Cluster 4, in
contrast, projects more along a complex combination of vectors
representing the CD25, CD45RA, CCR7, MIP1b, and GM-CSF,
although the precise expression patterns warrant additional
visualization methods. Another interesting observation was
that Cluster 6 appears to change between day 0 and day 7
postvaccination in both the unstimulated as well as stimulated
conditions. We see that Cluster 6 is spread out during the day
0 time point but starts to project along the lower left quadrant
that represents HLA-DR, perforin, and granzyme B postvacci-
nation. Thus, Cluster 6 has undergone changes in its marker
expression profile following influenza vaccination. However,
Cluster 6 did not significantly change in abundance between
time points and stimulation conditions (Table IV).
To further characterize the differences between these in-
fluenza virus–specific clusters, we created a heat map of mean
marker intensity per cluster across stimulation conditions and
visits (Fig. 4). From this heat map, we could discern the major
markers distinguishing each cluster. The heat map allows the
visualization of all markers at once, but we have also shown the
cell-level distribution of expression (pooled across stimulation
conditions and visits) for major markers in the form of dot plots
(Fig. 5). Both Cluster 3 and 4 showed low expression of CCR7 and
CD45RA, indicating that these are most likely effector memory
CD4+ T cell subsets (Figs. 4, 5A). Both clusters also showed high
expression of the activation marker CD154, which indicates an
ability to provide help via theCD40L/CD40pathway (Figs. 4, 5D).
Cluster 3 showed high levels of IFN-g, TNF-a, and IL-2, in
addition to the low levels of CCR7 and CD45RA, suggesting that
these were functional, cytokine-producing effector memory
CD4+ T cells (Figs. 4, 5B, 5C). Cluster 4 was also an effector
memory-like subset and expressed high CD154 (Figs. 4, 5A,
5D). However, its cytokine profile was very different from
Cluster 3, with low levels of IFN-g, IL-2, and TNF-a and a high
level of IL-17 (Figs. 4, 5B, 5C). This indicates that Cluster 4may
be a Th17-like effector memory subset. Cluster 6 showed a high
expression of granzyme B and CD107a, in addition to HLA-DR
and cytokines IFN-g, MIP1b, and TNF-a (Fig. 4). Interestingly,
among the six total CD4+ T cell clusters identified, we observed
that some clusters showed cytotoxicmarkers. Clusters 2, 5, and
6 showed high CD107a levels, Clusters 5 and 6 had high
granzyme B, and Cluster 5 had high perforin expression (Fig.
4). This indicates that there are cytotoxic CD4+ T cell subsets
among the total cytokine-producing CD4+ T cells that we
analyzed in this study.
Distribution of clusters within individuals
We next investigated the distribution of Clusters 3 and 4 by study
participant to determine if therewere any trends in the abundance
of the two clusters within an individual (Fig. 6). Some partici-
pants had negligible levels of both clusters. Another group of
participants had detectable levels of both clusters, but high
abundance of Cluster 3 and low abundance of Cluster 4. These
distinct subgroupswith specific trends in the abundanceofCluster
3 and Cluster 4 reflect an underlying heterogeneity in individual
biology. However, abundance of Cluster 3 or Cluster 4 did not
correlate with HAI response to the vaccine (data not shown).
FIGURE 4. Heat map of expression profiles for all six Clusters.
The heat map shows mean expression level [Arsinh (y/5), y = raw ex-
pression] across stimulation conditions and visits in color scale that
ranges from white (high) to black (low) for all markers on the panel
(labeled at bottom). Cluster label numbers are shown on the right. This
heat map allows approximate determination of the mean phenotypic
and functional characteristics of the cells that constitute the repre-
sented clusters. The heat map was produced with R package heatmap3,
as indicated in the Materials and Methods.
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With the advent of CyTOF, there has been a surge of single-cell
proteomic data on the phenotype and function of immune cells.
Having a staining panel of 37 different Abs presents an invaluable
opportunity to discover novel cell subsets and understand their
biological role. However, analyzing this high-dimensional dataset
poses several challenges, which must be overcome by advanced
computationalmethods (54).TheDRPmethoduses amultifaceted
approach consisting of denoising the input data, agglomerative
hierarchical clustering, and repeated pruning to obtain an
optimized cluster solution (Fig. 1).
Rather than denoising, Phenograph addresses the problem of
detecting rare phenotypes in noisy data using a two-step
procedure for construction of nearest-neighbor graphs (55). The
denoising step of DRP relies upon optimal selection of the
quantity of principal components to be retained for the
hierarchical clustering. Because principal components are linear
combinations of themarker intensity values, nonlinear dimension
reduction methods, such as t-distributed stochastic neighbor
embedding (56) and kernel-based density estimation extensions
such as automatic classification of cellular expression by non-
linear stochastic embedding (57), might identify phenotypes not
recovered by DRP. In our experience, t-distributed stochastic
neighbor embedding didmostly provide clear recovery of subsets
in this study’s dataset (Supplemental Fig. 3). Further, we do
recommend and did apply a nonlinear transformation of the
marker intensity values prior to estimating principal components.
Although beyond the scope of the current study, direct
comparison of results from DRP and PhenoGraph in several
simulated and real small datasets (#10,000 cells in total)wouldbe
highly instructive.
This studydidnot statistically correct acquiredCyTOFdata for
the nonspecific binding artifact of cross-reactivity. However, our
CyTOF panel has been optimally titrated as described (58) to
minimize nonspecific binding and spillover.
The DRP method described in this study allowed us to use
clustering to identify novel cell subsets and gain a deeper
understanding of their phenotypic and functional characteris-
tics. Recall that a “sample estimate” is defined as the value of a
parameter estimated from a sample drawn from a population (e.g.,
sample mean is an estimate of the population mean). The analysis
pipeline presented in this study first estimates what clusters of
cellsarepresent and,using thoseestimatedclusters, thenestimates
differences in the mean proportions of each of those clusters
between visits and between stimulation conditions. Note that the
FIGURE 5. Expression profiles of Cluster 3 and Cluster 4 represented as dot plots.
The expression (raw intensity) of some important characterizing markers expressed by Cluster 3 (blue) and Cluster 4 (green) are shown in the form
of dot plots. Each dot is an individual cell. Markers shown are (A) CCR7 and CD45RA, (B) IL-2 and IFN-g, (C) IL-17 and TNF-a, and (D) CD154 and
ICOS. The figure was prepared in SAS ODS Graphics (SAS Institute).
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second set of estimates (differences in mean proportions) thereby
depends upon the first set of estimates (cluster identities).
Especially rigorous control of type I error (false positives) would
propagate estimation (sampling) error in estimates of cluster
identities into subsequent estimates of differences in the mean
proportions of each of those clusters between visits and between
stimulation conditions. How to accomplish this error propagation
without resorting tocomputationallyprohibitivemethods requires
study and is beyond the scope of the present paper. As such, the
comparisonsof eachcluster’smeanproportionsbetweenvisits and
between conditions that are reported in the present paper should
be regarded as liberal (i.e., reject the null hypothesis too often)
to some unknown extent. In this study, we focused on CD4+
T cells, whose role is not completely understood in the context of
influenzavaccination.UsingDRPonourdataset,we identified two
cell clusters that either responded to influenza peptide stimula-
tion or influenza vaccination (Fig. 2, Table IV). Cluster 3 was
significantly above background at both day 0 and day 7, reflecting
pre-existing influenza virus–specific cells that presumably per-
sisted from previous vaccination(s) or infection(s) (Table IV). The
abundance of Cluster 3 did not change between time points for
either stimulation condition. Cluster 4, in contrast, was signifi-
cantly more abundant with stimulation at day 7 following
vaccination compared with stimulation at day 0 (prevaccination)
(Fig. 2, Table IV). However, the abundance of Cluster 4 did not
increase between the influenza peptide–stimulated condition and
theunstimulated condition at either timepoint. This implies that it
is a CD4+ T cell cluster that is responsive to influenza vaccination
but may not be responsive to the specific peptides used for
stimulation inourexperiments.Alternatively, thepvalues (adjusted
for multiple comparisons) for stimulated versus unstimulated
conditions may have not been significant because of the number
of cells sampled and/or because of stringent corrections for
multiple comparisons (Table IV).
Cluster 3, the pre-existing influenza virus–responsive CD4+
T cell subset, showed low CCR7 and CD45RA. This cluster
expressed cytokines like IL-2, TNF-a, and IFN-g, as well as high
levels of CD154 (Figs. 4, 5). This corresponds to a functionally
ready effector memory subset that is present prior to TIV
immunization. The abundance and reactivity of this cluster may
depend on factors like previous vaccine experience and the Ag
exposure history of the participants.
FIGURE 6. Distribution of Cluster 3 and Cluster 4 within each participant.
The distribution of cluster abundance (square root of proportion of CD4+ T cells) for Clusters 3 and 4 is shown by participant, separately for each
combination of visit and stimulation condition. Each line represents a single study participant. Color-coding is by individual to show how the
abundance of cells differs between clusters for that individual. Square-root transformation (vertical axes) facilitates visual separation of individuals.
The figure was prepared in SAS ODS Graphics (SAS Institute). Stim, stimulated with HA+NP peptide mix; Unstim, unstimulated.
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BothClusters 3 and 4 seem to be effectormemory subsetswith
low CCR7 and CD45RA expression (Figs. 4, 5A). Their cytokine
expression profiles were distinct as Cluster 3 showed high IL-2,
TNF-a, and IFN-g, whereas Cluster 4 mainly expressed IL-17
(Figs. 4, 5). These detailed analyses of Clusters 3 and 4 underscore
the role ofCD4+memoryTcell subsets in influenzavirus infection.
We also noted that both Cluster 3 and Cluster 4 had high
expression of CD154 or CD40L (Fig. 4). This could potentially
mean that they can help CD8+ T cell activation by dendritic
cell licensing through the CD40L/CD40 pathway (59, 60).
In addition, we also observed that Cluster 4 showed some
expression of ICOS and PD-1 compared with other clusters (Fig.
4). This suggests that these may be Tfh-like cells, although we
lackedotherTfhmarkers or the ability to functionally verify this.
We did not see correlations of either of these two clusters
with HAI response (data not shown). This could be due to
heterogeneity in responsiveness in the sampled population or
because theHApeptides used to stimulateCD4+Tcell responses
represent only a subset of the HA Ags used in HAI assays.
Furthermore, the insensitivity/inaccuracy of the HAI assay,
interval-censoring of serial dilution data, or the complexity of
factors, including participant vaccine history and individual
variation, and missing data could influence results for HAI
titers. In any case, these influenza virus–specific memory
T cells might contribute to protection from disease. This is in
accordance with previous studies that have shown that they
play a protective role, even in the absence of B cells and CD8+
T cells (61).
Clusters 1, 2, 5, and6werenot influenzavirus responsive in that
they did not significantly increase in abundance with influenza
virus peptide stimulation (Table IV). These clusters also did not
increase significantly after influenza vaccination. Most of these
clusterswere very rare (Table III), and therefore,wemay not have
collected enough cells to find significant differences from
background. It was previously shown that cells producing
cytokines in the absence of in vitro stimulation are biased toward
a late effector phenotype and are enriched in CMV-reactive
cells (in CMV-positive individuals) (62). Cluster 6 was initially
of some interest because of an inverse correlation between
California strain HAI titer and Cluster 6 abundance at day 0 but
not day 7 (Supplemental Fig. 4). However, this correlation was
possibly driven by a single extreme value, which made it hard to
evaluate the validity of this finding. Additionally, therewas some
evidence that Cluster 6 may be responsive to the influenza
vaccine, based on visual inspection of the star plots (Fig. 3).
However, the abundance of Cluster 6 did not change signifi-
cantly before and after vaccination (Fig. 2, Table IV). Cluster 6
also did not increase in abundance following influenza virus
peptide stimulation (Table IV). Heat maps from expression data
pre- and postvaccination did not show major changes (data not
shown), indicating that the star plots were possibly picking up
subtle and complex shifts in its marker expression profile (34).
From the heat map, we saw that Cluster 6 had a late effector
phenotypewith expression of cytokines likeMIP1b, TNF-a, and
IFN-g (Fig. 4).This cluster also expressedCD107a and granzyme
B. It is possible that our experimental limitations precluded the
identification of changes in the abundance of Cluster 6 between
stimulation conditions and time points. Alternatively, the change
in the expression profile of this cluster (Fig. 3)might be related to
changes taking place in other influenza-specific subsets. Without
knowing if Cluster 6 is influenza virus–specific or vaccine
responsive, it is difficult to fully understand the implications of
its qualitative transformation following influenza vaccination.
However, given the marker expression profile, it is interesting
to speculate that this could reflect a relationship between late
effectorCD4+Tcell accumulation inCMV-positive individuals and
poor response to influenza vaccine, as previously described (63).
In this study, statistical testing for differences in marker
expression levels was not performed because cluster analyses are
designed to segregate cells into clusters that are as distinctive as
possible with respect to expression. The risk of false positives can
therefore become inflated if testing for differences in expression is
performed in the same sample used for clustering. As such, a
reliable test of differences in expression levels among clusters
would need to be performed in a new independent sample of cells.
It would also have been interesting to characterize CD8+ T cell
responses in addition to CD4+ T cells. However, we did not
conduct anyclustering or analysis of influenzavirus–specificCD8+
T cells because of low responding cell numbers. In this study, we
used a limited set of influenza peptides for stimulation, and it is
possible that some responses were missed. This may also explain
the lack of expansion of CD4+ T cells. Overall, the observable
responses are limited to the set of influenza peptides that we used
for stimulation.
Another interesting finding from this study was that different
participants seemed tohavedifferent distributions of the influenza
virus–responsive clusters (Fig. 6). Some participants had a low
abundance of both clusters, suggesting they were simply poor
responders. Of those with higher responses, there tended to be a
pattern, with a higher abundance of Cluster 3 and a lower
abundance ofCluster 4. Such variations in influenzavirus–specific
clusters could be due to exposure history or other unknown host
factors. Such host differences could affect differential levels of
protective responses to influenza vaccination, as seen especially in
the elderly.
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Supplementary Figure S1 1 
 2 
 3 
Figure S1. Gating of cytokine producing cells prior to denoised ragged pruning. 4 
Total CD4
+
 T cells were gated for various cytokines. Left column shows unstimulated 5 
controls, and right column shows influenza peptide stimulated samples. Top to bottom: 6 




















 Supplementary Figure S2 11 
   12 
 13 
Figure S2. Sampling distribution and final cluster solution after down-sampling. 14 
(A) Sampling distribution cell counts per combination of participant, visit, and 15 
stimulation condition following stratified random down-sampling. Proportions are of 16 
CD4
+
 T cells. Since participants differ among studies and batches, counts are, more 17 
exhaustively, per each combination of study, batch, participant, visit, and stimulation 18 
condition. Three separate stratified random down-samplings were performed: results 19 
shown are for the third of these three. The spike in the histogram is the result of placing 20 
the maximum down-sampling quantity per stratum at 88 cells. Down-sampling was 21 
designed to 1) reduce computational memory requirements and time by reducing total 22 
quantity of cells input to DRP and 2) reduce inequality in cell counts among strata so that 23 
strata contribute less unequally to the DRP cluster solution. All down-sampling was at ~ 24 
50% of original sample size. SD = standard deviation. Figure was generated in SAS® 25 
ODS Graphics 9.4. (B) DRP final cluster solution derived from three stratified random 26 
50% down-samplings. Heatmap was produced with R package heatmap3 and edited with 27 




Supplementary Figure S3 29 
 30 
 31 
Figure S3. t-SNE plot for final cluster solution. Each datum is a single cell, labeled by 32 
cluster assignment: 3 = blue, 4 = green, 6 = magenta. t-SNE partially recovers clusters 33 
identified via DRP. Figure was generated using base R (www.r-project.org) and R 34 
package tsne. 35 
36 




Figure S4. Regression analysis of cluster abundance and HAI titer. HAI titer 41 
(California strain) plotted against the proportion of cells of Cluster 6 under the influenza 42 
peptide stimulation condition at (A) Day 0 and (B) Day 7. Each I-bar (I) denotes the 43 
censored interval of a titer observation in the two-fold dilution series. Figure was 44 
generated in SAS
®
 ODS Graphics 9.4 (SAS
®
 Institute, Cary, North Carolina, USA).  45 
